Quintiles, IMS merger completed

By Melissa Fassbender contact

- Last updated on GMT

(Image: QuintilesIMS)
(Image: QuintilesIMS)

Related tags: Ims health, Stock market

IMS Health has completed its merger with Quintiles, forming QuintilesIMS – one of the world’s largest healthcare information portfolios.

The merger was initially announced​ in May of this year, with new senior management roles announced​ in late August. 

Today, IMS Health shares were halted from trading on the NYSE and will no longer be traded.

Per the merger agreement, each IMS Health share was automatically converted into 0.3840 of a share of Quintiles stock at the time of the merger.

The merger is intended to accelerate growth in the combined company​,” Phil Bridges, senior director, Corporate Communications, told Outsourcing-Pharma.com. “The portfolios of the two companies are complementary and there is little overlap in the service portfolios​.”

According to Bridges, as QuintilesIMS the two companies would have had combined 2015 revenues of $7.2bn, a combined equity market capitalization of approximately $19bn, and an enterprise value of approximately $25bn.

The new company will combine extensive healthcare information, technology and services solutions to drive efficiencies across the entire life science product cycle from R&D through commercial operations​,” said Bridges. 

IMS Health’s information assets include more than 15 petabytes of encrypted and secure complex healthcare data, more than 500m anonymous patient records, and more than 85% coverage of global pharma sales, according to the company.

Bridges said client response has been “overwhelmingly positive as they recognize the benefits the merger of these two very diverse, but complementary companies represent​.”

However, there has been some hesitation​ from industry analysts. As Andrew Schafer, President at Industry Standard Research (ISR) previously told us, the integration of both companies’ data will be one of the key success factor to the merger. He expects the merger to “shake things up​” as the pace of change​ in the CRO industry continues to increase.

Related news

Show more

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Because When It's On the Line... Capability Matters.

Because When It's On the Line... Capability Matters.

Baxter BioPharma Solutions | 01-Oct-2022 | Product Brochure

Baxter’s BioPharma Solutions business supports leading pharmaceutical companies in meeting their commercialization objectives by providing scientific expertise,...

Related suppliers

Follow us


View more